...
首页> 外文期刊>The American Journal of Cardiology >Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin (CATCH) registry).
【24h】

Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin (CATCH) registry).

机译:基于肝素的抗凝期间住院期间血小板减少症患者的六个月随访(来自肝素引起的血小板减少症后的并发症(CATCH)注册)。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Thrombocytopenia is a predictor of adverse outcomes in patients with acute coronary syndromes and in critically ill patients. The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry was designed to explore the incidence, management, and clinical consequences of in-hospital thrombocytopenia occurring during heparin-based anticoagulation in diverse clinical settings. We conducted a prospective observational study of 37 United States hospitals participating in the CATCH registry to assess the relation of in-hospital thrombocytopenia to long-term outcomes. A total of 2,104 patients at increased risk of developing in-hospital thrombocytopenia or thrombosis were identified, and the 6-month mortality and rehospitalization rates were determined. Thrombocytopenia was not a significant predictor of 6-month mortality. In an adjusted model for in-hospital death in this cohort, thrombocytopenia had an odds ratio of 3.59 (95% confidence interval 2.24 to 5.77). The postdischarge mortality rate at 6 months was 9.7%. No significant difference was observed in the long-term mortality between patients who developed thrombocytopenia and those who did not. Thrombocytopenia was a weak, but statistically significant, predictor of a composite of mortality and rehospitalization at 6 months (hazards ratio 0.80, 95% confidence interval 0.65 to 0.98, p = 0.03). In conclusion, the 6-month mortality rate among heparin-treated patients with thrombocytopenia is high, although the risk independently related to thrombocytopenia appears to be restricted to the acute hospital phase.
机译:血小板减少症是急性冠状动脉综合征和重症患者不良结局的预测指标。肝素引起的血小板减少症后的并发症(CATCH)注册表旨在探讨在各种临床环境中基于肝素的抗凝治疗期间院内血小板减少症的发生率,管理和临床后果。我们对参加CATCH登记册的37家美国医院进行了一项前瞻性观察性研究,以评估院内血小板减少与长期预后的关系。总共确定了2104例发生院内血小板减少症或血栓形成的风险增加的患者,并确定了6个月的死亡率和再次住院率。血小板减少症不是6个月死亡率的重要预测指标。在该人群的院内死亡校正模型中,血小板减少症的优势比为3.59(95%置信区间为2.24至5.77)。 6个月时的出院后死亡率为9.7%。发生血小板减少症的患者与未发生血小板减少症的患者的长期死亡率无明显差异。血小板减少症是6个月死亡率和住院治疗综合指标的弱预测指标,但有统计学意义(危险比0.80,95%置信区间0.65至0.98,p = 0.03)。总之,尽管单独与血小板减少有关的风险似乎仅限于急性住院阶段,但接受肝素治疗的血小板减少症患者的6个月死亡率很高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号